**Claims**

1. A pharmaceutical composition comprising, as a therapeutically active agent, a parathyroid hormone; and an absorption enhancer, and a polymer comprising a plurality of alkaline groups, wherein a concentration of said polymer in the composition is at least 10 weight percent of the total weight of the composition, said absorption enhancer being a substituted or non-substituted fatty acid or a salt thereof.

2. The composition of claim 1, wherein at least a portion of said alkaline groups are carboxylate groups.

3. The composition of claim 2, wherein at least a portion of said carboxylate groups are in a form of a pharmaceutically acceptable salt.

4. The composition of any one of claims 1 to 3, wherein said absorption enhancer comprises NAC or a salt thereof.

5. The composition of any one of claims 1 to 4, wherein a concentration of said absorption enhancer is at least 50 weight percent.

6. The composition of any one of claims 1 to 5, wherein a concentration of said polymer is at least 20 weight percent.

7. The composition of any one of claims 1 to 6, wherein a total concentration of said absorption enhancer and said polymer is at least 80 weight percent.

8. The composition of any one of claims 1 to 7, wherein a concentration of said alkaline groups in the composition is at least 0.1 millimoles per gram.

9. The composition of any one of claims 1 to 8, wherein said polymer is a crosslinked polymer.

10. The composition of any one of claims 1 to 9, wherein said polymer comprises a polysaccharide.

11. The composition of claim 10, wherein said polysaccharide is selected from a starch derivative and a cellulose derivative.

12. The composition of any one of claims 1 to 11, wherein said polymer comprises carboxymethyl groups.

13. The composition of any one of claims 1 to 12, wherein said polymer is characterized by a pKa in a range of from 1.2 to 7.5.

14. The composition of any one of claims 1 to 13, wherein said therapeutically active agent is or comprises teriparatide or eneboparatide (AZP-3601).

15. The composition of any one of claims 1 to 14, being in a form of a unit dosage form.

16. The composition of claim 15, wherein an amount of said alkaline groups in the unit dosage form is at least 0.03 millimoles.

17. The composition of claim 15 or 16, wherein said unit dosage form comprises at least 50 mg of said absorption enhancer.

18. The composition of any one of claims 15 to 17, wherein said unit dosage form comprises one or more tablet.

19. Use of the composition of any one of claims 1 to 18, in the manufacture of a medicament for the treatment of a condition treatable by said therapeutically active agent, wherein the medicament is to be orally administered.

20. The use according to claim 19, wherein said condition is selected from osteoporosis, conditions associated with a bone fracture or bone defect, osteoarthritis, and hypoparathyroidism.